Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LPTX

Leap Therapeutics Inc

Oct 24 • 04:00PM ET

0.4785

+0.0109 2.33 %

Healthcare • Biotechnology • USA • NASD

Peers: AFMD XNCR MTEM KZR ADAP PRQR NKTR RIGL BLRX BGMS

| Held by: PINK VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.59	Insider Own	41.05%	Shs Outstand	41.44M	Perf Week	-13.24%
Market Cap	19.83M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	29.93M	Perf Month	38.25%
Enterprise Value	1.98M	PEG	-	EPS next Q	-	Inst Own	20.16%	Short Float	8.35%	Perf Quarter	40.90%
Income	-65.69M	P/S	-	EPS this Y	-	Inst Trans	-5.31%	Short Ratio	0.75	Perf Half Y	19.65%
Sales	0.00M	P/B	3.47	EPS next Y	-	ROA	-129.47%	Short Interest	2.50M	Perf YTD	-83.36%
Book/sh	0.14	P/C	1.09	EPS next 5Y	-	ROE	-183.72%	52W High	4.79 -90.01%	Perf Year	-84.26%
Cash/sh	0.44	P/FCF	-	EPS past 3/5Y	27.46% 34.28%	ROIC	-1148.94%	52W Low	0.22 115.25%	Perf 3Y	-94.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.91% 20.35%	Perf 5Y	-97.93%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	20.28%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.34	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.02	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.34	EPS Q/Q	21.94%	SMA20	-16.45%	Beta	-0.06	Target Price	5.50
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	17.50%	Rel Volume	0.14	Prev Close	0.47
Employees	52	LT Debt/Eq	0.00	Earnings	Aug 14 BMO	SMA200	-9.73%	Avg Volume	3.35M	Price	0.48
IPO	Jan 25, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-37.93% -	Trades		Volume	476,472	Change	2.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-25	Downgrade	Robert W. Baird	Outperform → Neutral	$9 → $1.25
Jan-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$8
Oct-04-21	Initiated	Mizuho	Buy	$6
Jun-04-21	Resumed	Robert W. Baird	Outperform	$5
Jun-29-20	Initiated	Piper Sandler	Overweight	$6
Feb-11-20	Initiated	Robert W. Baird	Outperform	$6
Nov-15-19	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-13-19	Resumed	Raymond James	Outperform
Mar-07-17	Initiated	Ladenburg Thalmann	Buy	$18

Oct-20-25 07:00AM	Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 (PR Newswire) -5.24%
Oct-09-25 07:00AM	Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire) -8.55%
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) -17.98%
Oct-06-25 10:54AM	Leap Therapeutics Shares Jump on $59M Winklevoss-Led Crypto Deal (CoinDesk) +43.15%
09:00AM	Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire)
07:00AM	Loading…
Sep-25-25 07:00AM	Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 (PR Newswire) +12.63%
Aug-14-25 07:00AM	Leap Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) -28.14%
Jun-23-25 07:00AM	Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives (PR Newswire) -18.04%
May-13-25 07:00AM	Leap Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire) +6.64%
Apr-25-25 01:00PM	Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting (PR Newswire)
Apr-15-25 07:00AM	Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer (PR Newswire) +9.77%
Mar-31-25 01:42PM	Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript (Seeking Alpha)
Mar-26-25 01:29PM	Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer (Benzinga) +16.88%
07:05AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
07:00AM	Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study (PR Newswire)
07:00AM	Loading…
Jan-28-25 07:00AM	Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study (PR Newswire) -71.11%
Jan-06-25 07:00AM	Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-26-24 07:00AM	Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference (PR Newswire) +5.16%
Nov-13-24 07:00AM	Leap Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire) -7.69%
Sep-30-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Aug-12-24 07:00AM	Leap Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
May-13-24 08:31AM	Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress (GuruFocus.com)
07:00AM	Leap Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-29-24 04:01AM	Pipeline Moves: Investigator-led trial of Lillys merestinib in solid tumours terminated (Clinical Trials Arena) -5.54%
Apr-11-24 08:30AM	Leap Therapeutics Announces $40 Million Private Placement (PR Newswire)
Mar-20-24 09:35AM	Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks (Zacks) +15.91%
Mar-18-24 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Jan-16-24 05:05PM	Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-03-24 07:00AM	Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients (PR Newswire) +12.67%
04:05PM	Loading…
Dec-11-23 04:05PM	Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +11.28%
Nov-21-23 07:00AM	Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +17.87%
Nov-13-23 07:00AM	Leap Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-03-23 09:55AM	These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird (TipRanks) +26.92%
Sep-05-23 07:00AM	Leap Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-14-23 07:00AM	Leap Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Jul-12-23 07:00AM	Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients (PR Newswire) +6.19%
Jun-20-23 12:30PM	Leap Therapeutics Announces Reverse Stock Split (PR Newswire) -23.22%
Jun-04-23 07:11AM	10 Hot Penny Stocks To Buy (Insider Monkey)
May-25-23 05:10PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) -9.82%
May-15-23 07:00AM	Leap Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-26-23 04:05PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) +6.37%
Apr-12-23 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire) +17.67%
Apr-04-23 11:10AM	Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Mar-24-23 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire)
Mar-17-23 12:26PM	BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate (Benzinga) -16.85%
Mar-16-23 04:05PM	Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 (PR Newswire) +6.05%
Jan-17-23 05:13PM	Leap Therapeutics to acquire Pennsylvania biotech in all-stock deal (American City Business Journals) -14.66%
09:24AM	Leap Therapeutics Shares Fall After Flame Biosciences Acquisition (Benzinga)
08:00AM	Leap Therapeutics Acquires Flame Biosciences (PR Newswire)
Jan-11-23 07:00AM	Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference (PR Newswire)
Nov-21-22 07:00AM	Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-16-22 05:20AM	Leap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021) (Simply Wall St.) -5.12%
Nov-14-22 07:00AM	Leap Therapeutics Reports Third Quarter 2022 Financial Results (PR Newswire) +12.62%
Nov-07-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Oct-26-22 08:19AM	Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-17-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Oct-12-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer (PR Newswire)
Oct-05-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Sep-27-22 08:15AM	Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures (GlobeNewswire)
Sep-07-22 07:00AM	Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference (PR Newswire) +8.02%
Sep-06-22 07:00AM	Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors (PR Newswire) +8.72%
Sep-04-22 06:05PM	Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress (PR Newswire)
Aug-12-22 07:00AM	Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute (PR Newswire)
07:00AM	Leap Therapeutics Reports Second Quarter 2022 Financial Results (PR Newswire)
Jul-21-22 07:47AM	Do Institutions Own Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares? (Simply Wall St.)
Jul-14-22 11:37AM	Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal (Zacks)
11:34AM	Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome (Zacks)
Jul-12-22 11:20AM	Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA (Zacks) -8.80%
11:13AM	Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint (Zacks)
07:00AM	Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer (PR Newswire)
Jul-11-22 11:58AM	Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion (Zacks) -6.72%
06:19AM	Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech (Zacks)
Jul-08-22 11:48AM	Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug (Zacks)
11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why (Zacks)
Jul-07-22 11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
Jul-04-22 11:49AM	Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU (Zacks)
Jun-29-22 12:44PM	Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why (Zacks)
12:34PM	Graybug (GRAY) to Review Strategic Alternatives, Stock Up (Zacks)
Jun-28-22 11:52AM	Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD (Zacks) -6.82%
Jun-27-22 07:00AM	Leap Therapeutics to Host Virtual R&D Day on July 12, 2022 (PR Newswire) +9.09%
Jun-17-22 11:16AM	Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry (Zacks)
Jun-13-22 12:01PM	Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development (Zacks) -6.54%
Jun-10-22 10:51AM	Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study (Zacks)
Jun-09-22 10:48AM	Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED (Zacks) -6.67%
Jun-08-22 10:14AM	Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease (Zacks) +10.09%
Jun-07-22 11:30AM	Praxis (PRAX) Tanks on Negative Data From Depression Study (Zacks)
11:23AM	Global Blood's (GBT) Candidates for SCD Get Two FDA Tags (Zacks)
Jun-06-22 10:13AM	GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix (Zacks) -6.84%
09:48AM	Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study (Zacks)
Jun-03-22 10:51AM	Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails (Zacks) +6.36%
10:49AM	Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug (Zacks)
Jun-02-22 12:09PM	Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy (Zacks)
11:24AM	Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug (Zacks)
May-31-22 11:26AM	GSK to Boost Vaccine Portfolio With Affinivax Acquisition (Zacks)
May-26-22 05:00PM	Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting (PR Newswire) -7.50%
11:18AM	Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe (Zacks)
May-25-22 12:07PM	INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study (Zacks) +6.25%

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. Its novel therapies are designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LPTX

Leap Therapeutics Inc

Upgrade your FINVIZ experience